Clinical Trials Browser

Triple Negative Breast Neoplasms × atezolizumab × 30 days × Clear all

NCT05498896 2026-05-08

BARBICAN

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms